About this Research Topic
Pediatric vitreoretinal diseases include retinopathy of prematurity (ROP), Coats disease, persistent fetal vasculature syndrome (PFV), Stargardt disease, X-linked retinoschisis (XLR) and other vitreoretinal diseases involving genetic predisposition, infection, prematurity or trauma happened in children. Because of the distinct anatomic and physiological features, pediatric vitreoretinal diseases can be very different from those in adults. There are a number of unique considerations for the management of pediatric patients and therapeutic strategies. Pediatric vitreoretinal diseases often impair vision and even lead to permanent blindness in millions of people worldwide. Nonetheless, vision impairments could have been prevented by early diagnosis and treatment in some patients.
Over the last several decades, progress on our understanding and treatment in the pediatric vitreoretinal diseases has been revolutionary. For example, novel imaging techniques, such as optical coherence tomography angiography (OCTA), scanning laser ophthalmoscopy, and ultra-wild field fundus fluorescein angiography, have been employed in the early detection and diagnosis of the retinal disease. Anti-vascular endothelial growth factor (VEGF) was used in the treatment of ROP, Coats disease and CNV, as a prominent factor for suppressing vascular leakage and angiogenesis. Recombinant adeno-associated virus (AAV) vector-based gene therapy showed positive outcomes in several phase I/II clinical trials and has been approved for the treatment of RPE65-mutation-associated retinal dystrophies.
Although we have made significant advances in our understanding of pediatric retinal disease, there is much left to unravel. To reach a better outcome for patients with pediatric vitreoretinal disease, an in-depth understanding of, mechanism, genetics, clinical features and preclinical/clinical trial results are urgently needed.
In this research topic, we welcome reviews and original articles to provide the recent progress in pediatric vitreoretinal diseases and seek potential novel therapeutic strategies. These include, but are not limited to, genetic and molecular mechanisms of pediatric vitreoretinal diseases, diagnosis, clinical features, imaging findings, epidemiology, preclinical research, and clinical trials. We look forward to your contributions.
Subtopics of interest include, but not limited to:
• Retinopathy of prematurity (ROP)
• Coats disease
• Familial exudative vitreoretinopathy (FEVR)
• Persistent fetal vasculature syndrome (PFV)
• Stargardt disease
• X-linked retinoschisis (XLR)
• Stickler syndrome
• Retinoblastoma (Rb)
• Juvenile macular degeneration
• Pediatric retinal detachments
• Pediatric retina vascular diseases
• Cell therapy trials
• Genotyping/phenotyping studies
Over the last several decades, progress on our understanding and treatment in the pediatric vitreoretinal diseases has been revolutionary. For example, novel imaging techniques, such as optical coherence tomography angiography (OCTA), scanning laser ophthalmoscopy, and ultra-wild field fundus fluorescein angiography, have been employed in the early detection and diagnosis of the retinal disease. Anti-vascular endothelial growth factor (VEGF) was used in the treatment of ROP, Coats disease and CNV, as a prominent factor for suppressing vascular leakage and angiogenesis. Recombinant adeno-associated virus (AAV) vector-based gene therapy showed positive outcomes in several phase I/II clinical trials and has been approved for the treatment of RPE65-mutation-associated retinal dystrophies.
Although we have made significant advances in our understanding of pediatric retinal disease, there is much left to unravel. To reach a better outcome for patients with pediatric vitreoretinal disease, an in-depth understanding of, mechanism, genetics, clinical features and preclinical/clinical trial results are urgently needed.
In this research topic, we welcome reviews and original articles to provide the recent progress in pediatric vitreoretinal diseases and seek potential novel therapeutic strategies. These include, but are not limited to, genetic and molecular mechanisms of pediatric vitreoretinal diseases, diagnosis, clinical features, imaging findings, epidemiology, preclinical research, and clinical trials. We look forward to your contributions.
Subtopics of interest include, but not limited to:
• Retinopathy of prematurity (ROP)
• Coats disease
• Familial exudative vitreoretinopathy (FEVR)
• Persistent fetal vasculature syndrome (PFV)
• Stargardt disease
• X-linked retinoschisis (XLR)
• Stickler syndrome
• Retinoblastoma (Rb)
• Juvenile macular degeneration
• Pediatric retinal detachments
• Pediatric retina vascular diseases
• Cell therapy trials
• Genotyping/phenotyping studies
Keywords: Pediatric vitreoretinal disease, Pediatric retinal disease, Retinopathy of prematurity, Coats disease, Familial exudative vitreoretinopathy (FEVR)
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
